Vidatec

Quick links to important sections

Vidatec

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vidatec

What is Vidatec?

Vidatec is a pharmaceutical medication containing the active substance ceritinib. It belongs to a class of medicines known as antineoplastic agents, specifically categorized as tyrosine kinase inhibitors (TKIs). This medication is designed to target and interfere with specific proteins that contribute to the growth and spread of certain types of cancer cells.

Mechanism of Action

The primary function of Vidatec involves the inhibition of an enzyme called anaplastic lymphoma kinase (ALK). In some individuals, a genetic alteration causes the ALK gene to fuse with another gene, leading to the production of an abnormal ALK protein. This abnormal protein acts as a continuous signal for cancer cells to divide and multiply uncontrollably.

By binding to these ALK proteins, Vidatec blocks the signaling pathway. This process is intended to slow down or stop the progression of the disease and may help in shrinking existing tumors. Because it targets specific molecular markers found on the surface or inside of cancer cells, it is often referred to as a targeted therapy.

Therapeutic Use

Vidatec is utilized in the management of non-small cell lung cancer (NSCLC) that has been identified as ALK-positive. This identification is typically confirmed through specialized diagnostic testing prior to the commencement of treatment. It is generally used in cases where the cancer is advanced or has spread to other parts of the body (metastatic).

As a systemic treatment, the medication travels through the bloodstream to reach cancer cells throughout the body. The use of this therapy is determined based on the specific genetic profile of the tumor rather than a one-size-fits-all approach to lung cancer care.

What side effects are possible with Vidatec?

Possible Side Effects and Safety Information

The safety profile for Vidatec (Cetirizine Dihydrochloride) is established through official government regulatory documents, which classify adverse reactions by frequency and physiological system-organ class.

Documented Adverse Reactions

Adverse effects are grouped into standard regulatory frequency categories:

  • Common (may affect up to 1 in 10 people): Reactions listed frequently include somnolence (drowsiness), fatigue, headache, dizziness, and dry mouth. Gastrointestinal effects such as nausea and abdominal pain are also commonly documented.
  • Uncommon and Rare reactions: Less frequent effects are listed, including agitation, paresthesia (tingling sensation), rash, and tachycardia (fast heart rate).

System-Organ Classifications and Serious Events

Side effects are classified across systems, including Nervous System Disorders and Gastrointestinal Disorders. The regulatory profile documents infrequent but serious adverse reactions, categorized as Rare or Very Rare. These include severe hypersensitivity reactions (e.g., anaphylactic shock and angioneurotic oedema), convulsions, syncope, and disturbances in liver function (hepatitis).

Population-Specific and Time-Related Safety Notes

The official safety information includes mandatory restrictions for specific populations. The product is contraindicated in individuals with severe renal impairment or end-stage renal disease, due to the drug's clearance profile. Safety information also notes that effects like somnolence are more likely to occur at the start of treatment and may be dose-related. Furthermore, a risk of severe pruritus (itching) is noted in regulatory text upon discontinuation after long-term daily use.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented manifestations and required emergency actions for an overdose of Vidatec (Cetirizine Dihydrochloride) as described in government regulatory sources.

Documented Overdose Presentations and Actions

Classification Official Regulatory Statements
Documented Manifestations The primary reported symptoms are drowsiness and somnolence. Other documented effects include central nervous system (CNS) manifestations such as restlessness, confusion, stupor, dizziness, headache, and fatigue. Severe events, particularly with intake of at least five times the recommended daily dose, may involve convulsions and tachycardia (rapid heart rate), alongside urinary retention [2.6, 1.2].
Population Note Overdose symptoms in infants and young children may initially present as irritability or fussiness before the onset of sedation [1.1, 2.2].
Emergency Actions Regulatory documents explicitly mandate that individuals must seek emergency medical attention immediately and consult a doctor immediately [1.3, 1.4]. Immediate contact with emergency services (such as 911 or the local equivalent) is required if the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened [2.2].
Management Symptomatic and supportive treatment is recommended for overdose management [1.2, 1.3]. The official prescribing information states that there is no known specific antidote to cetirizine [2.6, 1.6].

The official overdose profile dictates that due to the risk of severe systemic and CNS complications, professional medical assessment and observation are required in cases of suspected overdose. Management is constrained to providing supportive care, as the official regulatory documents confirm the absence of a specific reversal agent.

Therapeutic Uses of Vidatec

What Vidatec Treats: Main Uses and Benefits

Vidatec (Cetirizine Dihydrochloride) is commonly used to help with symptomatic relief across domains where additional symptomatic support is needed, contributing to easing the overall symptom load. It is used to help address symptoms such as sneezing, runny nose, itchy, red, watery eyes, and discomfort caused by hives. This provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.


Addressing Allergic Symptoms of the Nose and Eyes

This therapeutic domain is relevant in contexts involving Seasonal or Perennial Allergic Rhinitis, where symptoms are linked to irritative or fluctuating manifestations. Vidatec is commonly used to help with symptom clusters that may become intense or disruptive, such as persistent sneezing, profuse runny nose, and noticeable nasal itching. It is also applied in addressing accompanying ocular symptoms, including watering and pruritus of the eyes, which helps patients cope more steadily with symptom fluctuations.


Relief for Chronic and Acute Allergic Skin Discomfort

Applied across domains where additional symptomatic support is needed, Vidatec is relevant in conditions characterized by periods of heightened symptoms, specifically urticaria (hives) and generalized itching. It helps address symptoms that create noticeable physiological strain, offering symptomatic relief that is often required during phases of increased distress or discomfort.

Quick Fact: Relief for Pruritus Vidatec is commonly used to help manage systemic itching (pruritus) associated with allergic skin conditions, assisting with maintaining functional stability.


Providing Extended, Systemic Symptom Support

Used in settings where short-term symptom stabilization is important, the medication may offer sustained symptomatic support that is generally considered relevant. This sustained support is applied when symptoms become temporarily overwhelming for both adult and pediatric patient groups, assisting with maintaining functional stability and supporting general well-being during symptomatic phases.

Regulatory References

  1. Cetirizine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility rules for Vidatec (Cetirizine Dihydrochloride) are defined by absolute prohibitions and restrictions based on age, organ function, and physiological status, as documented in governmental regulatory sources.

Eligibility Scope

Category Official Regulatory Status / Classification
Populations for whom use is allowed Adults, adolescents ge 12 years, and children 6 to 11 years (tablet formulation). Use is also established for children 6 months and older (oral solution/syrup, depending on indication).
Populations for whom use is contraindicated Patients with known hypersensitivity to cetirizine, its parent compound hydroxyzine, or any piperazine derivatives.
Age-related eligibility rules The tablet formulation is not recommended for children under 6 years. Safety and efficacy are not established for infants under 6 months for general use.
Condition-specific eligibility rules Use is contraindicated in patients with severe renal impairment or End-Stage Renal Disease (ESRD) ( CL cr < 10 mL/min).
Pregnancy and lactation eligibility Pregnancy: Use is recommended only when necessary. Lactation: Excreted into human milk; some labels state use is not recommended.
Eligibility-related restrictions Dose adjustment is required for patients with moderate to severe renal impairment or combined hepatic and renal impairment. Caution is also advised for patients with a predisposition to urinary retention or a risk of convulsions.

Connection to the Overall Eligibility Profile

Official regulatory documents establish who can and cannot use Vidatec through a set of absolute prohibitions that apply to individuals with severe hypersensitivity or the most compromised renal function. For all other approved populations, eligibility is defined by conditional use, requiring mandated dosage adjustments for organ impairment and recommending caution for individuals with certain comorbidities like a predisposition to urinary retention or risk of convulsions.

What should I know about interactions with other medicines?

Vidatec Interactions with other medicines and products

Vidatec's official interaction profile is structured around its metabolic fate and transport within the body, as documented in governmental regulatory labeling. The co-administration of Vidatec with other medicines or products is subject to specific restrictions based on pharmacokinetic changes.

Interactions affecting Vidatec exposure:

  • Strong Enzyme Modulators: Co-administration with potent inhibitors of the primary metabolizing enzyme (e.g., CYP3A4 inhibitors) is documented to significantly increase the concentration of Vidatec. Conversely, strong inducers of this enzyme may decrease Vidatec concentration, leading to a risk of reduced effectiveness.
  • Absorption Interference: Products that increase gastric pH (e.g., proton pump inhibitors) or that bind to Vidatec in the gut require specific timing separation to prevent a clinically significant reduction in Vidatec's absorption.

Interactions where Vidatec affects other medicines:

  • Vidatec is an established inhibitor of certain transport proteins (e.g., P-glycoprotein) and metabolizing enzymes. This action can increase the concentration of co-administered medicines that are sensitive substrates of these systems, requiring caution and potentially dose adjustment for the co-administered drug.

Official Regulatory Constraints:

  • Specific combinations with strong inducers are contraindicated or not recommended in the official label due to the risk of subtherapeutic exposure. Other combinations are classified as clinically significant and require mandatory dose modification or intensive clinical monitoring.

Mechanism of Action

The Mechanism of Action of Vidatec

Vidatec functions as an inhibitor with a dual-target strategy focused on cellular signaling pathways in peripheral tissues. The mechanism initiates with its inhibitory binding to Receptor Tyrosine Kinases (RTKs) and key components of the mTOR protein complex. This targeted interference simultaneously suppresses two major, interconnected communication networks inside the cell: the PI3K/AKT/mTOR and the Ras/MAPK signaling cascades.

By disrupting these pro-survival pathways, Vidatec shifts the cellular balance away from growth and maintenance. This mechanistic cascade leads to the core physiological consequence of cell-cycle arrest and promotes the re-establishment of sensitivity to programmed cell death (apoptosis). The final modulation of tissue cellularity results from this targeted suppression of proliferation and induction of cellular demise.

Dosage and Administration Information

How to Use Vidatec

Vidatec (Cetirizine Dihydrochloride) is administered according to standardized regimens. The medicine is primarily used via the oral route for long-term and seasonal symptom management, although an intravenous (IV) form is available for the short-term management of acute urticaria.


Standard Dosing and Frequency

Vidatec is commonly available in oral forms, including tablets, chewable tablets, and solutions. The standard oral regimen for adults and adolescents (12 years and older) is 10 mg administered once daily. For less severe presentations, a dose of 5 mg once daily may be used. The maximum allowed oral dose is 10 mg per 24 hours. The injectable solution is administered as a 10 mg IV push over one to two minutes, used as needed for acute episodes, not for chronic maintenance.

Administration Conditions and Adjustments

Vidatec oral forms can be taken with or without food. For practical administration, the 10 mg film-coated tablet is scored and may be broken in half to provide two equal 5 mg doses.

Dose Adjustment for Impairment: Because the medicine is primarily excreted by the kidneys, dose adjustments are required for individuals with decreased renal function. For example, those with moderate renal impairment typically receive 5 mg once daily, while those with severe impairment may require 5 mg every two days. No dose reduction is typically required for individuals with isolated hepatic impairment.

Missed Dose Protocol: If a dose is missed, individuals should resume the regular dosing schedule and must not take a double dose to compensate for the forgotten dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vidatec

This summary outlines the structure of the research evidence available for Vidatec (Cetirizine Dihydrochloride), describing what types of studies have been conducted, what they have explored, and what aspects of the research remain uncertain. This information is intended to provide context and is not a substitute for medical advice.

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Vidatec was studied for its use in managing seasonal allergies, or hay fever, through short-term Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies were conducted during periods of increased symptom activity, and research examined outcomes related to systemic or functional imbalance associated with allergy symptoms. Studies monitored patient-reported outcomes describing perceived discomfort from symptoms such as sneezing, runny nose, and itchy, watery eyes. The certainty remains low regarding the sufficiency of the evidence to draw conclusions about long-term outcomes over an entire allergy season because follow-up durations were limited in most primary RCTs.


Evidence for Use in Perennial Allergic Rhinitis (PAR)

For year-round allergies, the evidence base includes short-term RCTs with some long-term observational or safety extension studies. Studies explored how symptoms change over time for persistent allergic reactions, focusing on outcomes reflecting daily functioning or activity level. While some studies monitored patients for up to a year, the high-level evidence structure (RCTs) related to outcomes is primarily derived from shorter-term trials. Therefore, there is limited information for long-term outcomes regarding continuous observation over many years.


Evidence for Use in Chronic Hives (Urticaria) and Itching

Vidatec was studied for its use in conditions associated with acute or disruptive episodes, specifically chronic urticaria (hives) and generalized itching (pruritus). Research includes RCTs and studies focusing on patients whose symptoms showed an inadequate initial response. Researchers used validated scoring instruments to measure outcomes related to physical discomfort, such as the severity of hives and the intensity of itching. A research limitation frame is that studies examining higher-dose regimens for difficult-to-treat hives often have sample sizes that were modest and observation periods that were short.


Long-Term Studies and Extended Follow-up

For most of the studied conditions, long-term data related to outcomes are not fully established through primary RCTs. The evidence is derived from observational settings evaluating daily-life functioning, which helps contextualize how patients reported their experience but does not provide definitive long-term certainty. Limited information is available regarding long-term data related to the condition's observed pattern or the sustained measurement of the observed response.


Evidence in Special Populations

Research has explored Vidatec's use in several special groups. Specifically, studies was observed in both Adults and Children (including groups as young as 2 years old) for conditions characterized by fluctuating or episodic manifestations. However, the results apply only to the populations studied, and data for certain groups, such as the older adult population with complex health issues, remain insufficient. The research provides context but not individual predictions, and it is important to remember that study results reflect the specific conditions under which they were conducted.

Key Studies & References Cetirizine: MedlinePlus Drug Information (National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Vidatec (FAQ)


Q: How quickly does Vidatec start working after the first dose?

Studies and official product information indicate that the highest concentration of the active substance in the blood is typically reached within approximately one hour after an oral dose. This value reflects when the maximum concentration is typically measured.


Q: What happens if I stop taking Vidatec suddenly?

Official safety data notes a risk of developing severe itching (pruritus) in some patients who have been using the medicine daily for a long period of time and then stop suddenly. This severe itching may appear within a few days after discontinuation of the medicine.


Q: Can Vidatec be taken with food, or should it be on an empty stomach?

Vidatec may be taken either with food or without it. While taking it with food does not change the total amount of medicine absorbed by the body, official information indicates that food may decrease the rate at which the active substance is absorbed.


Q: Are there any known issues with taking Vidatec and alcohol?

No clinically significant interactions have been shown with a low blood alcohol concentration at the standard therapeutic dose. However, official information recommends caution if alcohol is consumed at the same time, as it notes the potential for a general reduction in alertness when both are used together.


Q: Does Vidatec interact with common pain relievers like ibuprofen or aspirin?

Official drug interaction studies performed with Vidatec have not reported clinically significant interactions with other common pain relievers or non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or aspirin.


Q: What is the expected duration of treatment with Vidatec?

The duration of treatment is variable and depends on the condition being addressed. The medicine is officially approved for use in managing both short-term, acute episodes and for the long-term, daily management of chronic health conditions.


Q: Does Vidatec affect blood pressure?

Changes in blood pressure are not listed among the common, uncommon, or rare documented side effects of Vidatec in official regulatory documents, according to reports of undesirable effects.


Q: Is there a generic version of Vidatec available?

Yes, the active ingredient in Vidatec, Cetirizine Dihydrochloride, is widely available as a generic drug in the United States and other regions globally. Official drug catalogues list these approved generic options.


Q: Can Vidatec be taken during pregnancy?

Official regulatory documents recommend that Vidatec be used during pregnancy only when necessary. Although limited human data are available, studies in animals have not indicated evidence of harm to the developing fetus.


Q: Is Vidatec safe while breastfeeding?

The active substance in Vidatec is known to be excreted into human milk. Some official labels state that use is not recommended, and caution is advised due to potential effects in the infant.


Q: Can children or adolescents use Vidatec?

Yes, the use of Vidatec is established and approved for adults, adolescents, and children. The specific minimum age for eligibility depends on the formulation and the approved use, generally ranging from 6 months to 6 years of age for different forms.


Q: What should I tell my pharmacist about when getting Vidatec?

Official guidance notes the importance of informing healthcare providers, including pharmacists, of any history of kidney or liver impairment, any known hypersensitivity to the medicine or its chemical family, and all other current medicines or supplements being used.


Q: Are there any dietary restrictions while taking Vidatec?

There are no specific dietary restrictions that are mandatory while taking this medication. While food may affect the speed of absorption, official information primarily cautions regarding the concurrent use of alcohol.


Q: Does Vidatec affect sleep patterns?

The official safety information documents somnolence (drowsiness) as a common side effect of Vidatec. Less commonly, other effects involving the nervous system, such as agitation or disturbances in sleep, have also been reported.


Q: Does Vidatec need to be stored in a special way?

Official storage instructions state that the medicine should be kept at room temperature, secured in its original container, and placed away from excessive heat and humidity. Some liquid formulations may also have an additional requirement to protect them from light.


Q: Why is the official name of Vidatec so complicated?

The official name, Cetirizine Dihydrochloride, is based on standard chemical nomenclature. This naming convention precisely describes the molecule's structure and chemical composition, which ensures global consistency and accuracy in identifying the active substance.


Q: Is Vidatec addictive or habit-forming?

Vidatec is officially not classified as a controlled substance by US federal regulators. This indicates that the medicine is not considered to carry a high potential for abuse or the development of physical dependence.


Q: Are there different forms of Vidatec (e.g., liquid, capsule)?

The active substance is formulated for oral use and is available in multiple forms, including various types of tablets (such as film-coated, chewable, and orally disintegrating), capsules, and an oral solution or syrup.


Q: What happens if I take Vidatec with grapefruit?

No specific interaction between Vidatec and grapefruit or grapefruit juice is documented in the official prescribing information for the product, unlike some other medicines.


Q: Does the strength of Vidatec affect the side effects?

Official safety information notes that certain side effects, specifically somnolence (drowsiness), are considered dose-related. This means the likelihood or severity of this specific effect may increase when a higher dose is used.


Q: How does Vidatec relate to my body's immune system?

Vidatec is an antihistamine that primarily blocks the action of histamine, a chemical involved in allergic reactions. Research has indicated that Vidatec does not significantly influence the immune response or suppress the immune system in clinical or laboratory settings.


Q: Is it safe to get a vaccine while taking Vidatec?

Official drug interaction checkers and databases generally do not show a known interaction between Vidatec and common vaccines. However, individual situations may require specific consideration.


How should Vidatec be stored and disposed of?

How to Store and Dispose of Vidatec

Vidatec (Cetirizine Dihydrochloride) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

The medication should be stored at room temperature, away from excess heat and moisture. Liquid forms may have the additional requirement to Protect from light. The product must be kept in its original container and secured with the cap tightly closed.

Child Safety and Stability

It is mandatory to store the medicine out of the sight and reach of children. Some liquid oral solutions may have a restricted in-use shelf-life, such as six months after the bottle is first opened.

Disposal Instructions

Unused or expired product should be returned via a drug take-back program or disposed of in the household trash after mixing with an undesirable substance (like coffee grounds) and sealing the mixture in a bag. The medicine must not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vidatec found in:

A-Z Index: